Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria

Publication date: July–August 2018Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 6, Issue 4Author(s): Murat Türk, Emek Kocatürk, Kübra Cüre, İnsu Yılmaz
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research